En Es
Categories

Industry News

Mast Group Enters into Multi-Country Distribution Agreement for Nanomix's eLab System

By Labmedica International staff writers
07 Nov 2022

Image: Nan?mix eLab is a mobile, hand-held immunoassay and chemistry diagnostic system (Photo courtesy of Nanomix)

Mast Group Limited (Liverpool, UK) and Nanomix (Emeryville, CA, USA) have entered into a multi-region distribution agreement wherein Mast will market and distribute the Nan?mix eLab system in the UK, Germany, France, Ireland and South Africa.


The Nan?mix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.


“This new agreement with Mast Group becomes our largest expansion to date within Europe for the Nanomix eLab system,” said Thomas Schlumpberger, Chief Executive Officer of Nanomix. “The Nanomix solution is a unique, breakthrough technology that offers mobile, timely diagnostic capability from a whole blood sample. The eLab system will help expedite sepsis and pneumonia diagnosis leading to more informed treatment decisions, thus improving patient outcomes and hospital clinical collaboration.”


“It has been a pleasure working with The Mast Group to bring this agreement to fruition. Mast has significant experience and presence in this increasingly complex and important area of critical infections, sepsis, and antibiotic stewardship,” said John Hardesky, Chief Commercial Officer of Nanomix. “Their team is experienced and is actively participating in clinical conversations and solutions to improve patient outcomes and impact hospital performance. We are excited to actively align with Mast on an aggressive execution plan to bring our technology to multiple markets throughout Europe.”


“The Mast Group has always been proud of its commitment and ability to offer innovative diagnostic products that help our customers,” added Sandy Daun, Sales and Marketing Director of Mast Group. “We are pleased to begin this long-term, strategic relationship with Nanomix which reinforces that commitment. The platform technology provides the right foundation for assay expansions which will complement the growth areas important to Mast and our customers.”


Related Links:
Mast Group Limited 
Nanomix 



E-mail Print
FaceBook Twitter Google+ Linked in

MAST GROUP

Mast Group is an independent manufacturer and supplier of diagnostic products for clinical, industrial and veterinary testing. The company offers an extensive range of microbiology and immunology products, as well as diagnostic products from several internationally renowned manufacturers for use in hospital pathology laboratories, universities and veterinary establishments.
Silver member
More info

Additional news

25 Jan 2023
Global Diagnostic Imaging Services Market Driven by Rising Prevalence of Chronic Diseases
The global diagnostic imaging services market was valued at USD 40.80 billion in 2021 and is expected to register a CAGR of 5.8% during the forecast period 2022-2030 to reach USD 67.94 billion in 2030, driven by the rising prevalence of chronic diseases, increasing elderly population, and rapid technological advancements in the healthcare diagnostic industry.
Read More
25 Jan 2023
Global Endoscopy Equipment Market Driven by Growing Hospital Investment in Advanced Instruments
The global endoscopy equipment market is projected to register a CAGR of 7% from USD 28.9 billion in 2022 to USD 40.6 billion by 2027, driven by increasing demand for endoscopy to diagnose and treat target diseases, rising investments, funds, and grants by governments and other organizations across the world, and growing focus by hospitals on investing in technologically-advanced endoscopy instruments and expanding endoscopy units.
Read More
25 Jan 2023
Point-of-Care Glucose Testing Market to Reach Almost USD 6 Billion by 2032
The global point-of-care (POC) glucose testing market is projected to register a CAGR of 4.3% during the forecast period from 2022 to 2032 to reach USD 5.8 billion by 2032, driven by a rise in the geriatric population, speed & precision of POC screening, increased adoption of electronic medical information, and the higher risk of COVID-19-related mortality associated with diabetes.
Read More
24 Jan 2023
Carolina Liquid Chemistries and Diazyme Enter Into Partnership
Carolina Liquid Chemistries, Corp. (CLC, Greensboro, NC, USA) and Diazyme Laboratories, Inc. (San Diego, CA, USA) have entered into a partnership to expand the test menu on the Diazyme DZ-Lite c270 benchtop clinical chemistry analyzer, allowing it to run both special and routine chemistries.
Read More
23 Jan 2023
Mindray Defibrillators Amongst the World’s First to Receive MDR Clearance
Mindray has received the CE marking for its defibrillation product family under the European Union's newest Medical Device Regulation (MDR). With the new rule tightening the controls for defibrillation devices, Mindray has become among the first manufacturers in the world to earn MDR accreditation for product quality and effectiveness.
Read More
23 Jan 2023
Siemens Launches Centre of Excellence for Immunoassay Instrument R&D in Ireland
Siemens Healthineers has launched a Center of Excellence for Immunoassay Instrument Research and Development (R&D) in Swords, Ireland. The new center will focus on unlocking breakthrough innovations in laboratory instruments used to detect infectious diseases, cancer and blood disorders.
Read More
20 Jan 2023
Global Intensive Care Unit (ICU) Equipment Market Driven By Increasing Neurological Diseases
The global intensive care unit (ICU) equipment market was valued at USD 6.6 billion in 2021 and is estimated to register a CAGR of 3.9% from 2022 to 2031 to reach USD 9.6 billion by 2031, driven primarily by a rise in the prevalence of neurological diseases.
Read More
20 Jan 2023
Bayer Acquires Imaging AI Platform Provider in the UK
Bayer (Leverkusen, Germany) has acquired Blackford Analysis Ltd. (Edinburgh, UK), a global strategic imaging AI platform and solutions provider. The acquisition is part of Bayer's strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow, with the goal to ultimately improve patient care and advance the company’s position in digital medical imaging.
Read More
16 Jan 2023
Medlab Middle East Sees 100% Increase in Exhibitor Numbers
Medlab Middle East, the MENA region’s largest medical laboratory exhibition and congress, has sold out its exhibitor space ahead of the show, which returns to the Dubai World Trade Centre from February 6 to 9, 2023.
Read More
Copyright © 2000-2023 TradeMed.com. All rights reserved. | Terms And Conditions